cushieblog.com
Next-Generation Compounds and Support Commercialization of Korlym(R)
Corcept markets Korlym® for the treatment of Cushing’s syndrome, a severe orphan illness that afflicts 20,000 people in the United States, approximately half of whom are cured by surgery. Cor…